Group items matching

in title, tags, annotations or url

One of the most challenging aspects of living a healthier lifestyle is trying to accomplish your goals while simultaneously dealing with a hectic schedule. Life is often full of responsibilities, and things can get so hectic that it's difficult to keep track of anything else outside of one's work. As a result, many people sacrifice their physical and mental health for work-which isn't worth it in the long run. While it might not be easy to manage a hectic schedule, there are ways to ease the burden. Here are some of the most popular best-practice tactics when dealing with a busy schedule. Write things down-even the things you'll do for fun One way to help deal with a hectic schedule is to ensure you write everything down. While some might think that it makes everything feel robotic, the fact that you can write down the things you plan to do for fun means you have something to look forward to. It also has the added benefit of bracing yourself mentally for various tasks. It's not easy to be spontaneous with fun events if you're already tired from work. Fortunately, writing things down and making them a part of your schedule can help your body adjust.

Pharmaceutical recalls are complicated and expensive, just like in any other business. Pharmaceutical recalls, however, pose a further risk because they might change both short- and long-term health effects. To ensure smooth recalls with few negative effects on public health, it is crucial to understand the pharmaceutical product recall procedure and the roles of each key player. Throughout the recall procedure, patient safety is crucially ensured by the FDA, pharmaceutical companies, pharmacy technicians, and other healthcare professionals. Learning about pharma recalls, procedures, and responsibilities is essential for guaranteeing patient safety for key actors like the Food and Drug Administration (FDA), manufacturers, and other medical specialists. RECALL CLASSIFICATIONS Recalls can fall into one of three categories-class I, II, or III-with class I being the most serious and lethal. Products that have the potential to result in serious, permanent complications or death are subject to Class I recalls. Class II recalls are recommended for product flaws that have a low likelihood of harmful events or that can result in reversible side effects. Last but not least, class III recalls typically arise from problems with packaging that do not pose a risk. Since they are frequently issued out of an abundance of prudence rather than due to any negative impacts, many people may even describe this kind of recall as benign.

From over-the-counter flu tablets to crucial antibiotics and antidepressants, medicines are running scarce in UK pharmacies this year, causing concerns among patients, the government, and the wider pharma industry. Drug shortages have accelerated over the past year due to a clutch of problems including the after-effects of the pandemic on supply chains, the war in Ukraine, and soaring input costs weighing on manufacturers. More recently, a sudden spike in respiratory infections - another by-product of Covid-19 that neither pharma companies nor the government were able to predict - has deepened the crisis, with 70 commonly taken drugs out of stock in Britain as of February. The problem is not unique to the UK. In a recent survey of groups representing pharmacies in 29 European countries, three quarters said shortages were worse this winter than a year ago, with a quarter reporting more than 600 drugs in short supply. The US is also facing significant shortages of popular prescription drugs like amoxicillin and Adderall, an ADHD medication. To some extent, the current disruption is laying bare wider challenges facing the industry for several years that were only exacerbated by the pandemic. The over-reliance on foreign suppliers for most active pharmaceutical ingredients (APIs) is one of them. This model has left companies more susceptible to supply shocks, which have in turn increased in frequency and severity due to pandemic lockdowns, the war in Ukraine and other issues such as the shortage of shipping containers. Pharma's long and opaque supply chains, alongside regulatory complexities, also mean it is taking longer for drugmakers to reconfigure manufacturing and distribution in times of additional need.

What will it take to get help from the government before an individual or sector breaks? Pharmacists raised questions after the Pharmaceutical Services Negotiating Committee (PSNC)'s 2023 Pharmacy Pressures Survey confirmed the ongoing pressures and health issues faced by the pharmacies. Pharmacists are not all shocked by the PSNC's survey report as they feel the same as what has been reported related to their businesses and health. They hope the government listens and work with them to find resolutions. "We are bullied into a corner," said Salim Jetha Chairman, Avicenna. "Unlike other industries, we can't increase our prices. Most of the daily calls I get from Independents is about financial health of their business and any cost cutting would be detrimental to patient care. Urgent holistic review is required." Bristol pharmacist Ade Williams said: "The report is a dire indictment, and I would also warn, likely an underestimate of the extent and detrimental impact of the ongoings pressures and squeeze on Community pharmacies." "If the closest interface of the NHS to communities and patients is so distressed, what does that mean for those that need and depend on us? We are notoriously very stoic, so this is a warning light, which, taken with workforce pressures, market-exit activity, and other reports raising concern about wellbeing and stress, must beg the question; what will it take to get help before the sector and individuals break?" he questioned. The survey results don't surprise Kent-based community pharmacist Amish Patel. He said, "I have been feeling exactly what has been reported for far too long. I'm burnt out and would say beginning to suffer with my own health because of it. Now it's for PSNC to talk to government, and government to listen and work with us to find resolutions."

British drugmaker AstraZeneca says it's confident that its new version of COVID-19 antibody treatment could protect immunocompromised patients against all known virus variants. Laboratory studies show the antibody, called AZD3152, neutralises all known variants of COVID-19 and AstraZeneca has support from regulators to make the treatment available by the end of this year, the company's vaccines head Iskra Reic said on Tuesday (April 18). AstraZeneca plans, pending more positive data and regulatory approval, to make the antibody available by the end of 2023. These types of therapies are most needed for people with compromised immune systems, either because of underlying conditions or because they are undergoing immune suppressing treatments. They account for nearly 2% of the global population. AstraZeneca's AZD3152, it new COVID-19 antibody, was acquired through a $157 million deal last year with British biotech start-up RQ Bio. The British drugmaker will likely make future investments like its current partnerships with RQ Bio but did not have any deals to announce, said Reic, a long-time AstraZeneca executive who has led the company's vaccines and immune therapies unit since it was formed in late 2021, during the pandemic.

Suffering a brain injury is no easy thing. The plurality of potential symptoms meets with the potential long-term effects to create a poor prognosis for many unfortunate enough to experience them. But new technological leaps could pave the way to a better quality of life. What is a Brain Injury? The above question might seem a simple one, with a simple answer. But brain injuries are by no means simple, and by no means simply defined. There are two major categories under which a brain injury can fall: hypoxic and traumatic. Of civil brain injury claims in the UK, traumatic brain injuries (TBIs) are the most common - with 95% of claims revolving around some form of traumatic injury or incident. TBIs are brain injuries suffered as a result of a specific or direct injury. The brain is damaged through direct contact or the transfer of force. A direct strike to the head is in an assault or a serious fall might compromise the cranium, sending shockwaves of energy through the brain and potentially crushing the skull into the cranial cavity. Alternatively, a car accident or sudden stop might see the brain bashed against the occipital bone, causing internal trauma and intracranial hypertension. Hypoxic brain injuries refer specifically to injuries caused as a result of loss of blood or oxygen to the head. These injuries reflect birth injuries that might lead to cerebral palsy, or serious medical events that might alter the brain's response to stimuli. How are Brain Injuries Diagnosed and Treated? While the potential causes of a brain injury are plain to see, diagnosing a brain injury is not as straightforward. There are immediate symptoms that can indicate brain injury, such as the 'fencing response' which can indicate a severe rotational brain injury. Conscious patients might also exhibit difficulty speaking, remembering key pieces of information or responding to any stimuli.

Community pharmacy could play an important role in proactive detection of heart valve disease (HVD), which remains under-recognised and under-detected in England, suggested a new report published by Wilmington Healthcare. Pharmacy bodies, including Royal Pharmaceutical Society (RPS), National Pharmacy Association (NPA) and Community Pharmacy England (CPE), have also endorsed the report, which encourages Integrated Care Boards (ICBs) to consider the innovative approach of detecting HVD with the help of community pharmacists. Despite HVD detection being a priority listed in the NHS Long Term Plan, a large number of people with HVD remained undiagnosed and untreated in the country due to lack of awareness of the disease prevalence. In June 2022, a pilot study was launched in Farnborough Primary Care Network (PCN), Hampshire, to evaluate the feasibility of using e-stethoscopes (digital auscultation) to detect this heart condition by a community pharmacist.

David Ogle and his family, who had been running the business for more than three decades, put it up for sale last year as they wanted to retire or pursue different business interests. Located in the Worcester city suburb of St Johns, DL Ogle Pharmacy dispenses an average of 12,000 items per month. The high-dispensing community pharmacy has been sold to brothers Ali and Mohammed Talib, Tapiwa Masamha and Chikondi Mlia, property adviser Christie & Co has revealed. The four brothers are also the owners of Gohil's Pharmacy and Whistlers Pharmacy in Lincolnshire. Carl Steer, Director - Pharmacy at Christie & Co. commented: "The sale was confidentially marketed but, within just a few days, interest was achieved from multiple parties, and we were able to present our client with an acceptable offer - this was a truly remarkable achievement but one that the long-standing business deserved.

What is Red Boost? Red Boost the Most Potent, Fast-Acting Formula for Boosting Male Sexual Performance. It helps to healthy blood flow support, enhanced smooth muscle function, emotional, long- lasting performances in the bedroom and strong sexual desire all while boosting natural reserves of energy and sex drive all day long Key Feature of Red Boost reviews Boosting Male Sexual Performance Healthy blood flow support Enhanced smooth muscle function Increased Sex Drive Further Energy and Vitality Easier Weight Loss and lower jones A Sharper and Healthier Recall Increased Performances and Youthful Stamina for your Love Life Support Healthy Blood Pressure Support Healthy Blood Sugar Supporting a Healthy Immune System

In a significant leap forward in the fight against HIV, the Medicines and Healthcare products Regulatory Agency (MHRA) has given the green light to two groundbreaking formulations of cabotegravir. Apretude 30 mg film-coated tablets and Apretude 600 mg prolonged-release suspension for injection are now authorized for preventing sexually transmitted HIV-1 infection in adults and adolescents weighing at least 35kg at increased risk. This approval marks a pivotal moment in HIV (human immunodeficiency virus) prevention, offering an alternative to existing standard pre-exposure prophylaxis or PrEP treatments. HIV, a virus notorious for compromising the immune system, has long been a global health concern. Cabotegravir, a member of the integrase inhibitor group, works by blocking a key enzyme necessary for the replication of HIV-1, thereby reducing the virus's ability to spread.

Extending its support for the Prescription Charges Coalition (PCC), the Pharmacists' Defence Association (PDA) is asking pharmacists in England to share their experiences of patients denying prescriptions due to financial issues. PDA members who have practiced in the country within the last 12 months are asked to complete the Prescription Charges Coalition survey by Sunday 28 January. The PCC is an alliance of more than 50 organisations campaigning to abolish unfair prescription charges for people with long-term conditions in England. All members of the coalition, including PDA and Royal Pharmaceutical Society (RPS), understand that if patients do not receive their prescribed medicines due to the cost, their health may deteriorate, and this can increase costs for the National Health Service (NHS).

The British Medical Association (BMA) on Wednesday announced that 33,869 junior doctors have voted in favour of extending the industrial action and the use of action short of strike (ASOS). With a turnout of 62 per cent, their demand stems from the ongoing campaign for complete pay restoration. The new mandate will last till September 19, starting on 3 April. The BMA junior doctors committee co-chairs, Dr Robert Laurenson and Dr Vivek Trivedi, expressed frustration at the year-long strike action, highlighting the government's avoidance tactics to tackle soaring waiting lists, access to GPs and staff shortages. "The government should see the urgency of the situation. Rather than waste time dragging out talks, they can come forward with a credible offer on pay right now. " "Instead, they could be celebrating a revitalised and reinvigorated junior doctor workforce, one that feels that their value has started to be restored. That would be an achievement worth celebrating for everyone and begin to finally turn the tide on the deteriorating workforce crisis," they said.

The UK government has decided to ban disposable vapes to tackle the rise in youth vaping and protect children's health, Prime Minister Rishi Sunak announced on Sunday (28 January 2024) during a visit to a school. Official figures revealed that the number of children using vapes has tripled in the past three years, with nine per cent of 11 - to 15-year-olds now affected by this rising trend. Disposable vapes are believed to be mainly driving the worrisome rise in youth vaping, with the number of 11- to 17-year-old vapers using disposables estimated to have increased by almost ninefold in the last two years. Sunak said: "As any parent or teacher knows, one of the most worrying trends at the moment is the rise in vaping among children, and so we must act before it becomes endemic. "The long-term impacts of vaping are unknown and the nicotine within them can be highly addictive, so while vaping can be a useful tool to help smokers quit, marketing vapes to children is not acceptable."

After a year-long divestment spree, LloydsPharmacy has entered into liquidation and appointed Turpin Barker Armstrong Accountants to handle the process. In its statement of affairs report, the liquidators confirmed that the pharmacy group owes £293m to 514 creditors. This includes £228m owed to the group's former owner Admenta UK and £50m to Aurelius Crocodile - a holding company that was used to control the pharmacy business. However, creditors are set to lose out on approximately £255m as only about £8.2m can be recovered for preferential creditors and £800,000 for its unsecured creditors, the liquidators said. The healthcare chain was acquired by Aurelius when the investment firm took over its parent company, McKesson UK in 2022 for £477m.

Global healthcare company Mundipharma and Vectura, an inhalation contract development and manufacturing organization, have entered into a collaboration agreement aimed at reformulating an asthma inhaler as part of their commitment to reducing the product's carbon footprint. The companies will be working together on incorporating an environmentally friendly propellant into the formulation of flutiform, a pressurised metered-dose inhaler (pMDI) used for asthma treatment, to achieve a near-zero-emissions product. Currently, the product uses the approved apaflurane hydrofluoroalkane 227 (HFA-227), a type of fluorinated greenhouse gas, as its propellant. The European Union's regulation on these types of greenhouse gases targets a two-thirds reduction in their usage and subsequent emissions by 2030. In a joint statement, companies revealed that work is already in progress to find an alternative to the HFA-227 gas. Yuri Martina, Chief Development and Medical Officer at Mundipharma, said: "This is the first step in our long-term plan to develop a near-zero-emissions asthma inhaler.

In a significant move to enhance the working conditions of over 50,000 postgraduate doctors in the National Health Service, NHS England has unveiled a series of measures aimed at providing greater choice and opportunities to the new entrants in the medical profession. With flexible rotas, reducing payroll errors, and easing the financial burden of course fees, the NHS has taken steps to address the issues faced by junior doctors in order to support their well-being. In recent announcement, 83 per cent of senior doctors and dentists accepted the government's pay offer. Alongside the junior doctors who still fighting for fair pay and recognition, the senior medical professionals demanded that the authorities help them tackle issues pertaining underfunding and overworking in the NHS. Junior doctors in training also often face challenges with frequent moves between trusts, leading to short notice changes in work schedules and duplicated inductions when transitioning to new hospitals. As a measure taken by the health serivces, the committee aims to review the minimum legal requirements for statutory and mandatory training, potentially halving the time burden for such training and allowing doctors to spend more time caring for patients as part of the long-term workforce plan.

Hey there, folks! Ever find yourself caught up in the throes of pain, wondering if there's a better way to handle it? You're not alone. In fact, according to recent stats, a whopping 93% of people worldwide grapple with pain annually. And get this: 1 in 3 folks deal with it every single day. Crazy, right? But here's the kicker: despite pain being such a prevalent issue, many folks aren't tackling it head-on. Yep, you heard that right. There's a whole lot of suffering going on, and not enough proactive pain management happening. So, what's the solution? Well, that's where our Pain Management Webinar swoops in to save the day! Picture this: an hour jam-packed with enlightening insights, carefully curated to arm you and your team with the tools needed to understand, manage, and ease pain in your patients' lives. Diving Deep: What's Inside the Webinar Alright, buckle up because we're about to dive into the juicy details of what this webinar has in store for you. 1. The Evolving Role of Pharmacists First up, we're shedding light on the evolving role of pharmacists in the realm of pain management. Yep, you heard that right. It's not just about doling out pills anymore. Pharmacists are becoming key players in the fight against pain, and we'll show you exactly how. 2. Decoding Pain Assessment Ever struggle to figure out just how much pain your patients are in? We feel you. That's why we're dedicating some time to decode the art of pain assessment. By the time you're done with this segment, you'll be a pro at understanding and quantifying your patients' pain levels. 3. #ListenToPain: A Campaign for Better Conversations And last but certainly not least, we're shining a spotlight on Haleon's #ListenToPain campaign. This bad boy is all about fostering better conversations between you and your patients. Trust us, folks, communication is key when it comes to pain management, and this campaign's got all the tools you need to nail those conversations. Tailored Jus

In response to the concerning surge in youth vaping, the UK government in January announced its decision to ban disposable vapes as a measure to safeguard the health of children. Prime Minister Rishi Sunak stated that while the long-term impacts of vaping were uncertain, the nicotine present in these products can be highly addictive. Therefore, he emphasised that "marketing vapes to children is not acceptable." Now, there's a stronger reason to crack down on vape sales as a new study has revealed that vaping or the use of e-cigarettes may increase the risk of developing heart failure. The study, which involved 175,000 adults in the United States, found that those who use e-cigarettes were 19 per cent more likely to develop heart failure over a four-year period. Dr Yakubu Bene-Alhasan, lead author of the study, from MedStar Health in Baltimore, underscored that an increasing number of studies are linking e-cigarettes with harmful effects, suggesting vaping "might not be as safe as previously thought." With further research, Dr Bene-Alhasan's team plans to uncover "a lot more about the potential health consequences and improve the information out to the public."

National Health Services (NHS) patients across England are set to experience a significant enhancement in accessing key healthcare services such as community nursing through the expansion of self-referral options that no longer require a GP appointment. The recent announcement is part of the NHS primary care access recovery plan and is set to offer hundreds of thousands more individuals each month the opportunity to refer themselves for essential services such as "incontinence support", "podiatry", or "hearing tests" without GP referrals. This move aims to alleviate the burden on general practitioners through self-referrals for more than 180,000 patients, allowing them to focus their time and resources on patients in need of immediate care and recover the long waiting times. As per the NHS data, approximately 200,000 people per month self-refer themselves which under the new plan will extend to additional critical services tailored to local population needs to "continue modernising GP, expand pharmacy services, and offer patients more choice in how they access care".

The incredible consequences that drug misuse has imposed on humans in the last few years make it one of the most pressing issues facing such nations. A person who is addicted to drugs or alcohol often turns to these substances as a crutch while they're going through tough times. Taking the drug regularly becomes habitual since it provides short-term relief without permanently resolving the issue. An important part of becoming sober is learning to substitute better routines for the addict's old, harmful ones. These self-care routines and healthy habits are much better ways to deal with stress. Here we will explain how healthy behavior throughout addiction recovery is simply one of many methods to adapt to life after treatment. Physical Activity Scientific studies have shown that physical activity increases levels of two hormones. dopamine and serotonin, which are linked to better mood. A more positive outlook, restful sleep, and enhanced general health are all possible outcomes of these hormones. In the early stages of your rehabilitation, it is wise to start an exercise regimen that you have never done before. You may find new sober friends and interactions, as well as inspiration to improve your physical health, by connecting with other people who share your interests in physical activity. In the early stages of recovery, having sober friends may be really helpful since it allows you to connect with those who understand what you're going through. Friendships formed in early recovery often continue long after the addict has left the program, according to many people in recovery.